Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.
Dimitris KardassisAnn-Charlotte EgnellMagnus ÅstrandSamuel J DanielsCarl WhatlingOla FjellströmAnders GabrielsenPublished in: Journal of the American Heart Association (2024)
URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04588727.
Keyphrases
- double blind
- placebo controlled
- open label
- endothelial cells
- clinical trial
- acute coronary syndrome
- phase iii
- percutaneous coronary intervention
- phase ii
- induced pluripotent stem cells
- study protocol
- pluripotent stem cells
- st elevation myocardial infarction
- antiplatelet therapy
- st segment elevation myocardial infarction
- randomized controlled trial
- nk cells